NSAID use and clinical outcomes in COVID-19 patients: A 38-center retrospective cohort study.

ABSTRACT:

Background

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain, fever, and inflammation but have been associated with complications in community-acquired pneumonia. Observations shortly after the start of the COVID-19 pandemic in 2020 suggested that ibuprofen was associated with an increased risk of adverse events in COVID-19 patients, but subsequent observational studies failed to demonstrate increased risk and in one case showed reduced risk associated with NSAID use.

Methods

A 38-center retrospective cohort study was performed that leveraged the harmonized, high-granularity electronic health record data of the National COVID Cohort Collaborative. A propensity-matched cohort of COVID-19 inpatients was constructed by matching cases (treated with

SUBMITTER: Reese JT 

PROVIDER: S-EPMC8077581 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature